These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 19667403

  • 1. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.
    Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F.
    Blood; 2009 Nov 19; 114(21):4696-702. PubMed ID: 19667403
    [Abstract] [Full Text] [Related]

  • 2. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
    Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ.
    Blood; 2009 Nov 19; 114(21):4687-95. PubMed ID: 19745070
    [Abstract] [Full Text] [Related]

  • 3. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
    Wei C, Jin XX, Cai H, Wang X, Zhuang JL, Zhou DB.
    Zhonghua Nei Ke Za Zhi; 2023 Apr 01; 62(4):416-421. PubMed ID: 37032137
    [Abstract] [Full Text] [Related]

  • 4. Molecular variant of hairy cell leukemia with poor prognosis.
    Arons E, Kreitman RJ.
    Leuk Lymphoma; 2011 Jun 01; 52 Suppl 2(Suppl 2):99-102. PubMed ID: 21599610
    [Abstract] [Full Text] [Related]

  • 5. Hairy cell leukaemia-variant: Disease features and treatment.
    Matutes E, Martínez-Trillos A, Campo E.
    Best Pract Res Clin Haematol; 2015 Dec 01; 28(4):253-63. PubMed ID: 26614904
    [Abstract] [Full Text] [Related]

  • 6. Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis.
    Forconi F, Cencini E, Sicuranza A, Sozzi E, Lauria F.
    Leuk Lymphoma; 2011 Jan 01; 52(1):15-23. PubMed ID: 21133731
    [Abstract] [Full Text] [Related]

  • 7. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
    Panovská A, Žák P, Jurková T, Arpáš T, Brychtová Y, Vašíková A, Hrabčáková V, Prchlíková A, Filipová M, Doubek M.
    Hematol Oncol; 2024 May 01; 42(3):e3280. PubMed ID: 38741354
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T, Błasińska-Morawiec M, Błoński J, Hellmann A, Hałaburda K, Konopka L, Kotlarek-Haus S, Potoczek S, Hansz J, Dmoszyńska A, Urasiński I, Zdziarska B, Dwilewicz-Trojaczek J, Hołowiecki J, Skotnicki AB.
    Eur J Haematol; 1999 Jan 01; 62(1):49-56. PubMed ID: 9918312
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cladribine in hairy cell leukemia.
    Belani R, Saven A.
    Hematol Oncol Clin North Am; 2006 Oct 01; 20(5):1109-23. PubMed ID: 16990111
    [Abstract] [Full Text] [Related]

  • 12. Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.
    Forconi F, Toraldo F, Sozzi E, Amato T, Raspadori D, Lauria F.
    Leuk Lymphoma; 2007 Dec 01; 48(12):2441-3. PubMed ID: 18067021
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
    Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
    Blood; 2012 Apr 05; 119(14):3330-2. PubMed ID: 22210875
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
    Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S.
    Blood Cancer J; 2016 Mar 11; 6(3):e404. PubMed ID: 26967821
    [Abstract] [Full Text] [Related]

  • 17. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
    Hacioglu S, Bilen Y, Eser A, Sivgin S, Gurkan E, Yildirim R, Aydogdu I, Dogu MH, Yilmaz M, Kayikci O, Tombak A, Kuku I, Celebi H, Akay MO, Esen R, Korkmaz S, Keskin A.
    Hematol Oncol; 2015 Dec 11; 33(4):192-8. PubMed ID: 25393847
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
    Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT.
    Clin Lymphoma Myeloma Leuk; 2017 Dec 11; 17(12):857-862. PubMed ID: 28778620
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
    Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ.
    Blood; 2016 Jan 21; 127(3):303-9. PubMed ID: 26492934
    [Abstract] [Full Text] [Related]

  • 20. Treatment of hairy cell leukemia-variant with cladribine.
    Tetreault SA, Robbins BA, Saven A.
    Leuk Lymphoma; 1999 Oct 21; 35(3-4):347-54. PubMed ID: 10706459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.